Halozyme Therapeutics Inc. (NASDAQ: HALO) has a price-to-earnings ratio that is above its average at 18.62x. The stock has a 36-month beta value of 1.26. Opinions on the stock are mixed, with 5 analysts rating it as a “buy,” 2 as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for HALO is 125.67M, and at present, short sellers hold a 6.28% of that float. On April 11, 2024, the average trading volume of HALO was 1.24M shares.
HALO) stock’s latest price update
The stock price of Halozyme Therapeutics Inc. (NASDAQ: HALO) has plunged by -2.12 when compared to previous closing price of 40.13, but the company has seen a -2.36% decline in its stock price over the last five trading sessions. Zacks Investment Research reported 2024-04-04 that The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here’s why you should take advantage.
HALO’s Market Performance
Halozyme Therapeutics Inc. (HALO) has experienced a -2.36% fall in stock performance for the past week, with a -4.66% drop in the past month, and a 12.26% rise in the past quarter. The volatility ratio for the week is 3.30%, and the volatility levels for the past 30 days are at 2.66% for HALO. The simple moving average for the last 20 days is -3.20% for HALO stock, with a simple moving average of 1.61% for the last 200 days.
Analysts’ Opinion of HALO
Many brokerage firms have already submitted their reports for HALO stocks, with TD Cowen repeating the rating for HALO by listing it as a “Outperform.” The predicted price for HALO in the upcoming period, according to TD Cowen is $54 based on the research report published on February 29, 2024 of the current year 2024.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see HALO reach a price target of $61. The rating they have provided for HALO stocks is “Buy” according to the report published on July 24th, 2023.
Goldman gave a rating of “Neutral” to HALO, setting the target price at $45 in the report published on July 24th of the previous year.
HALO Trading at 1.39% from the 50-Day Moving Average
After a stumble in the market that brought HALO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -12.71% of loss for the given period.
Volatility was left at 2.66%, however, over the last 30 days, the volatility rate increased by 3.30%, as shares sank -6.36% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +14.15% upper at present.
During the last 5 trading sessions, HALO fell by -2.36%, which changed the moving average for the period of 200-days by +15.06% in comparison to the 20-day moving average, which settled at $40.44. In addition, Halozyme Therapeutics Inc. saw 6.28% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at HALO starting from LaBarre Michael J., who sale 10,000 shares at the price of $42.27 back on Mar 13 ’24. After this action, LaBarre Michael J. now owns 156,558 shares of Halozyme Therapeutics Inc., valued at $422,730 using the latest closing price.
LaBarre Michael J., the SVP, CHIEF TECHNICAL OFFICER of Halozyme Therapeutics Inc., sale 10,000 shares at $41.64 during a trade that took place back on Mar 12 ’24, which means that LaBarre Michael J. is holding 156,558 shares at $416,370 based on the most recent closing price.
Stock Fundamentals for HALO
Current profitability levels for the company are sitting at:
- 0.41 for the present operating margin
- 0.77 for the gross margin
The net margin for Halozyme Therapeutics Inc. stands at 0.34. The total capital return value is set at 0.21. Equity return is now at value 222.07, with 15.75 for asset returns.
Based on Halozyme Therapeutics Inc. (HALO), the company’s capital structure generated 0.95 points at debt to capital in total, while cash flow to debt ratio is standing at 0.25. The debt to equity ratio resting at 18.27. The interest coverage ratio of the stock is 17.99.
Currently, EBITDA for the company is 422.43 million with net debt to EBITDA at 3.31. When we switch over and look at the enterprise to sales, we see a ratio of 7.68. The receivables turnover for the company is 3.54for trailing twelve months and the total asset turnover is 0.48. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.64.
Conclusion
To sum up, Halozyme Therapeutics Inc. (HALO) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
